
How the Novavax Vaccine Works

By Jonathan Corum and Carl Zimmer Dec. 30, 2020



The Maryland-based company Novavax has developed a protein-based coronavirus vaccine called **NVX-CoV2373**. The vaccine produced strikingly high levels of antibodies in early clinical trials. In September, the vaccine entered a Phase 3 clinical trial in the United Kingdom, and another one in the United States at the end of December. Those trials will show whether the vaccine is safe and effective.

Coronavirus Proteins


The SARS-CoV-2 virus is studded with proteins that it uses to enter human cells. These so-called spike proteins make a tempting target for potential vaccines and treatments.

CORONAVIRUS
Spike protein gene

The Novavax vaccine works by teaching the immune system to make antibodies to the spike protein.

Growing Spike Proteins

To create their vaccine, Novavax researchers started with a modified spike gene. They inserted the gene into a different virus, called a baculovirus, and allowed it to infect insect cells. The infected cells produced spike proteins that spontaneously joined together to form spikes, as they do on the surface of the coronavirus.



A similar method of growing and harvesting virus proteins is already used to make licensed vaccines for diseases including influenza and HPV.

Building Nanoparticles

The researchers harvested the spike proteins from the insect cells and assembled them into nanoparticles. While the nanoparticles mimicked the molecular structure of the coronavirus, they could not replicate or cause Covid-19.

Nanoparticle studded with spikes

Presenting the Spike

The vaccine is injected into the muscles of the arm. Each injection includes many spike nanoparticles, along with a compound extracted from the soapbark tree. The compound attracts immune cells to the site of the injection and causes them to respond more strongly to the nanoparticles.

Vaccine nanoparticles

Immunity-priming compound

Spotting the Intruder

Immune cells called antigen-presenting cells encounter the vaccine nanoparticles and take them up.

VACCINE NANOPARTICLES

Engulfing the vaccine

ANTIGEN-PRESENTING CELL

Digesting spike proteins

Presenting spike protein fragments

HELPER T CELL An antigen-presenting cell tears apart the spike proteins and displays some of their fragments on its surface. A so-called helper T cell may detect the fragments. If a fragment fits into one of its surface proteins, the T cell becomes activated. Now it can recruit other immune cells to respond to the vaccine.

Making Antibodies

Another type of immune cell, called a B cell, may also encounter the vaccine nanoparticles. B cells have surface proteins in a huge variety of shapes, and a few might have the right shape to latch onto a spike protein. If a B cell does latch on, it can pull the vaccine particle inside and present spike protein fragments on its surface.

If a helper T cell activated against the spike protein latches onto one of these fragments, it activates the B cell. Now the B cell proliferates and pours out antibodies that have the same shape as its surface proteins.

ACTIVATED HELPER T CELL

Activating the B cell

Matching surface proteins

VACCINE NANOPARTICLE

SECRETED ANTIBODIES

Stopping the Coronavirus

If vaccinated people are later exposed to the coronavirus, their antibodies can lock onto the spike proteins. The coronavirus cannot enter cells, and the infection is blocked.

ANTIBODIES

VIRUS

Killing Infected Cells

The Novavax vaccine can also trigger another kind of protection by destroying infected cells. When a coronavirus invades, infected cells put fragments of its spike protein on their surface. Antigenpresenting cells can activate a type of immune cell called a killer T cell. It can recognize coronavirus-infected cells and destroy them before they have a chance to produce new viruses.

ANTIGEN-PRESENTING CELL

Presenting a spike protein fragment


ACTIVATED KILLER T CELL

INFECTED CELL

Beginning to kill the infected cell


Remembering the Virus

Novavax's vaccine would be easier to distribute and store than the vaccines from Pfizer-BioNTech and Moderna. While those vaccines have to be kept frozen, NVX-CoV2373 can stay stable for up to three months in a refrigerator. But if the vaccine does turn out to be effective, scientists won't know for sure how look may



Vaccine Timeline

January, 2020 Novavax begins work on a coronavirus vaccine.



A screen showing protein structures at a Novavax lab in Maryland. Andrew Caballero-Reynolds/Agence France-Presse

May Novavax launches clinical trials for their vaccine.

July The U.S. government awards Novavax \$1.6 billion to support the vaccine's clinical trials and manufacturing.

August Novavax launched a Phase 2 trial on 2,900 people in South Africa.



Preparing an injection in Johannesburg, South Africa. Joao Silva/The New York Times

September Novavax launches a Phase 3 trial with up to 15,000 volunteers in the United Kingdom. The trial is expected to deliver results in early 2021.

Dec. 28 Novavax launches a Phase 3 trial with 30,000 people in the United States. The trial had been delayed because of problems with manufacturing the doses required for the study.

2021 If its clinical trials succeed, Novavax expects to deliver 100 million doses for use in the United States in 2021.

Sources: National Center for Biotechnology Information; Nature Reviews Immunology; Science; Maria Elena Bottazzi, Baylor College of Medicine.

Tracking the Coronavirus

United States



Latest Maps and Data

Cases and deaths for every county



Vaccine Distribution

Where vaccines have been reported given



Your Places

Build your own dashboard to track cases



Hospitals Near You

Patients hospitalized and I.C.U. beds remaining



Restrictions

What is open and closed in each state



Deaths Above Normal

The true toll of the pandemic in the U.S.



Cities and Metro Areas

Where it is getting better and worse



Nursing Homes

The hardest-hit states and facilities



Colleges and Universities

Cases at more than 1,700 schools

World



Latest Maps and Data

Cases and deaths for every country



Deaths Above Normal

The true toll of coronavirus around the world

Health



Vaccines

Track their development

2	10
2	3

Treatments

Rated by effectiveness and safety

Countries

Brazil

Germany

Mexico

U.K.

Canada

India

Spain

United States

France Italy

States, Territories and Cities

South Dakota Alabama Iowa New Hampshire Alaska Kansas **New Jersey** Tennessee Arizona New Mexico Texas Kentucky New York Arkansas Louisiana Utah California Maine **New York City** Vermont Colorado Maryland North Carolina Virginia Connecticut Massachusetts North Dakota Washington Ohio Delaware Michigan Washington, D.C. Florida Oklahoma West Virginia Minnesota Georgia Mississippi Oregon Wisconsin Hawaii Missouri Pennsylvania Wyoming Idaho Montana Puerto Rico Illinois Nebraska Rhode Island Indiana Nevada South Carolina

Data

Frequently Asked Questions About the Covid Data Access the Open Source Covid Data